Literature DB >> 3732890

Differing acute phase responses in Crohn's disease and ulcerative colitis.

S H Saverymuttu, H J Hodgson, V S Chadwick, M B Pepys.   

Abstract

Thirty eight patients with Crohn's disease and 30 patients with ulcerative colitis have been assessed using the technique of faecal excretion of 111Indium granulocytes to quantify precisely acute inflammatory activity. At the time of each faecal granulocyte measurement the serum concentration of the acute phase protein C-reactive protein and the erythrocyte sedimentation rate were estimated. C-reactive protein concentration was significantly higher in Crohn's disease than ulcerative colitis both overall and particularly in relation to given levels of granulocyte excretion. No such distinction was observed between the erythrocyte sedimentation rates in the two diseases. The present findings show that the acute phase response differs significantly between Crohn's disease and ulcerative colitis. Patients with ulcerative colitis may be constitutionally different from those with Crohn's disease and unable to mount a major acute phase response to their own disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732890      PMCID: PMC1433572          DOI: 10.1136/gut.27.7.809

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis.

Authors:  H E LOCKHART-MUMMERY; B C MORSON
Journal:  Gut       Date:  1960-06       Impact factor: 23.059

2.  Immune-mediated emigration of neutrophils into the lumen of the small intestine.

Authors:  J E Bellamy; N O Nielsen
Journal:  Infect Immun       Date:  1974-04       Impact factor: 3.441

3.  Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease.

Authors:  S H Saverymuttu; A M Peters; J P Lavender; M B Pepys; H J Hodgson; V S Chadwick
Journal:  Gastroenterology       Date:  1983-12       Impact factor: 22.682

Review 4.  Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein.

Authors:  M B Pepys; M L Baltz
Journal:  Adv Immunol       Date:  1983       Impact factor: 3.543

5.  Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis.

Authors:  E A Fagan; R F Dyck; P N Maton; H J Hodgson; V S Chadwick; A Petrie; M B Pepys
Journal:  Eur J Clin Invest       Date:  1982-08       Impact factor: 4.686

6.  Overlap in the spectrum of non-specific inflammatory bowel disease--'colitis indeterminate'.

Authors:  A B Price
Journal:  J Clin Pathol       Date:  1978-06       Impact factor: 3.411

7.  Solid phase radioimmunoassays for human C-reactive protein.

Authors:  B Shine; F C de Beer; M B Pepys
Journal:  Clin Chim Acta       Date:  1981-11-25       Impact factor: 3.786

8.  Short-term course and prognosis of Crohn's disease.

Authors:  F T De Dombal; I L Burton; S E Clamp; J C Goligher
Journal:  Gut       Date:  1974-06       Impact factor: 23.059

9.  Double-contrast radiography: colonic inflammatory disease.

Authors:  H J Williams; D H Stephens; H C Carlson
Journal:  AJR Am J Roentgenol       Date:  1981-08       Impact factor: 3.959

10.  The acute-phase response in (NZB X NZW)F1 and MRL/l MICE.

Authors:  C Rordorf; H P Schnebli; M L Baltz; G A Tennent; M B Pepys
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

View more
  39 in total

1.  Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow up study.

Authors:  D Ludwig; S Wiener; A Brüning; K Schwarting; G Jantschek; K Fellermann; M Stahl; E F Stange
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

Review 2.  Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Authors:  Eduardo Garcia Vilela; Henrique Osvaldo da Gama Torres; Fabiana Paiva Martins; Maria de Lourdes de Abreu Ferrari; Marcella Menezes Andrade; Aloísio Sales da Cunha
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

3.  Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.

Authors:  Marla Cindy Dubinsky
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

4.  Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease.

Authors:  Bülent Yılmaz; Seyfettin Köklü; Osman Yüksel; Serap Arslan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

5.  Plasma viscosity in inflammatory bowel disease.

Authors:  A J Lobo; S C Jones; L D Juby; A T Axon
Journal:  J Clin Pathol       Date:  1992-01       Impact factor: 3.411

6.  Correlation between triggering receptor expressed on myeloid cells-1 and clinical disease activity in Chinese patients with ulcerative colitis.

Authors:  Shulan Zhang; Jing Luo; Bingbing Shen; Lijun Li; Chaojun Hu; Ping Li; Chuiwen Deng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 7.  Biomarkers in inflammatory bowel disease: current practices and recent advances.

Authors:  Heba N Iskandar; Matthew A Ciorba
Journal:  Transl Res       Date:  2012-02-01       Impact factor: 7.012

8.  Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease.

Authors:  M Z Mazlam; H J Hodgson
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

Review 9.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

10.  Clinical significance of serum procalcitonin in patients with ulcerative colitis.

Authors:  Shigeo Koido; Toshifumi Ohkusa; Kazuki Takakura; Shunichi Odahara; Shintaro Tsukinaga; Toyokazu Yukawa; Jimi Mitobe; Mikio Kajihara; Kan Uchiyama; Hiroshi Arakawa; Hisao Tajiri
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.